Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Key result
Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.
Why the study?
Does edoxaban prevent stroke or systemic embolism in patients with atrial fibrillation compared to warfarin?
Population
Patients with atrial fibrillation
Comparison
Edoxaban (once-daily regimens) vs Warfarin
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Edoxaban offers a safer alternative to warfarin for atrial fibrillation; confirms and extends randomized evidence for direct oral anticoagulants.
Structured PICO
Does edoxaban prevent stroke or systemic embolism in patients with atrial fibrillation compared to warfarin?
P
Population
Patients with atrial fibrillation
I
Intervention
Edoxaban (once-daily regimens)
C
Comparator
Warfarin
O
Outcome
Stroke or systemic embolismcomposite
Once-daily edoxaban is noninferior to warfarin for stroke prevention in atrial fibrillation and reduces the risk of bleeding and cardiovascular death.
Cite This Study
Giugliano et al. (2013) studied this question. Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.